Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual MeetingGlobeNewsWire • 05/18/25
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?Zacks Investment Research • 05/15/25
Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)Seeking Alpha • 05/14/25
Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)Seeking Alpha • 05/12/25
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock UpZacks Investment Research • 05/09/25
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/08/25
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline CatalystsSeeking Alpha • 05/05/25
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to DeclineZacks Investment Research • 05/01/25
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving AverageZacks Investment Research • 05/01/25
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company UpdatesGlobeNewsWire • 05/01/25
Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a BetZacks Investment Research • 04/29/25
Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders FoundationPRNewsWire • 04/23/25
Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – NTLAGlobeNewsWire • 04/15/25
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLAAccesswire • 04/14/25
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLAPRNewsWire • 04/14/25
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewsWire • 04/14/25
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Lawsuit - NTLAAccesswire • 04/14/25
NTLA DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - NTLAAccesswire • 04/14/25
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmBusiness Wire • 04/14/25
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc. (NTLA) ShareholdersAccesswire • 04/14/25
Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLAPRNewsWire • 04/14/25
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) - April 14, 2025 Deadline to Join - Contact Levi & KorsinskyAccesswire • 04/14/25